From May 13 to 15, the 94th API Chinaand the 92nd PHARMCHINAgrandly opened at the National Exhibition and Convention Center (Shanghai). The events gathered thousands of outstanding pharmaceutical enterprises, authoritative industry experts and upstream and downstream partners across the whole industrial chain to jointly explore new trends for high-quality development of the pharmaceutical industry.
Nanjing Vcare PharmaTech Co.,Ltd. (Nanjing Vcare), together with its production base Hubei Tianshu Pharmaceutical Co., Ltd.（Tianshu Pharmaceutical）, showcased one-stop full-industry chain CRO/CDMO solutions for pharmaceutical R&D. Boasting solid R&D and innovation strength, a sound product supply system and professional customized technical services, the company drew wide attention and gained high recognition from industry insiders on site.
Deep Engagement in Industry Events, Exclusive Booth Highlights Core Strength
Co-hosted API China and PHARMCHINA focused on hot industry topics including pharmaceutical industrial innovation and upgrading, supply chain optimization and technological process iteration, building an integrated platform for product display, technical exchanges, business negotiations and resource docking for exhibitors.
Leveraging the strong industrial aggregation effect of the exhibitions, Nanjing Vcare set up a dedicated booth at Stand 3F23, fully displaying its core technological achievements and profound expertise in pharmaceutical research and development, API, pharmaceutical intermediates and custom synthesis. During the exhibitions, numerous pharmaceutical enterprises and R&D institutions visited the booth for on-site observation, in-depth consultation and business cooperation discussions.
Focus on Innovative R&D, Full-chain Services Consolidate Industrial Competitive Advantages
At this exhibition, Nanjing Vcare fully presented its integrated CRDMO service model, covering the whole industrial chain from early-stage drug research, process optimization and pilot scale-up to commercial production. This mature service system has been fully verified by the market. Up to now, the company has served more than 300 domestic and overseas pharmaceutical enterprises, assisted clients in obtaining over 80 generic drug production approvals and more than 50 innovative drug clinical trial approvals, with over 120 cooperative projects in the critical registration and application phase.
Supported by a sophisticated R&D and production system, Nanjing Vcare can steadily supply over 3,000 types of supporting intermediates, impurities and APIs, forming a diversified product portfolio with complete categories, reliable quality and stable supply. The company’s professional R&D team was stationed on-site throughout the event, introducing process advantages and customized service plans, analyzing industrial technical difficulties, and precisely matching personalized R&D and production demands of clients, winning unanimous praise for its professional services.
Further Industrial Cooperation, Dual Empowerment Expands Industrial Development Layout
During the exhibitions, Nanjing Vcare seized opportunities for industry exchanges to connect with high-quality industrial chain resources and conduct in-depth communications with industry experts and partners. Through technical seminars and business negotiations, the company kept abreast of cutting-edge industrial trends and broadened its industrial layout vision. Meanwhile, it reached multiple preliminary cooperation intentions relying on high-quality products and professional services, laying a solid foundation for subsequent market expansion, technical collaboration and in-depth industrial chain cooperation.
With professional industry attainments, robust R&D capabilities and sound market reputation, Nanjing Vcare has greatly enhanced its brand popularity, industry reputation and influence during the dual exhibitions, further consolidating its core competitive edge in the biomedical supply chain.
Stay True to Original Aspiration, Continuously Empower High-quality Industrial Upgrading
Participation in the 94th API China and 92nd PHARMCHINA serves as a vital opportunity for Nanjing Vcare to demonstrate comprehensive strength, connect high-quality industrial resources and expand domestic and overseas market presence.
Going forward, Nanjing Vcare will actively adapt to industrial development trends, deepen in-depth industrial chain collaboration, and commit itself to delivering cost-effective pharmaceutical products and integrated customized solutions for clients at home and abroad. The company strives to boost quality improvement, efficiency enhancement and transformation and upgrading of the pharmaceutical industry, safeguard public medication safety, and continuously fuel the high-quality and sustainable development of the global biomedical sector.
Talent Concept
Recruitment
Follow Us
